Caveolin-1 and polymerase i and transcript release factor: New players in insulin-like growth factor-I receptor signaling

Journal of Endocrinological Investigation

Volumn 36, Issue 3, 2013, Pages 204-208

  Hamoudane, M ^a,b   Maffioli, S ^a   Cordera, R ^a   Maggi, D ^a   Salani, B ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b ABDELMALEK ESSAADI UNIVERSITY   (Morocco)

Author keywords

Caveolin 1; Cavin 1; IGF i; PTRF

Indexed keywords

CAVEOLIN; CAVEOLIN 1; METFORMIN; POLYMERASE I AND TRANSCRIPT RELEASE FACTOR; PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; CANCER CELL; CANCER INHIBITION; CAVEOLA; CELL MEMBRANE; DOWN REGULATION; ENDOCYTOSIS; GENE EXPRESSION; HUMAN; INTERNALIZATION; MULTIPLE CANCER; OVARY CARCINOMA; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CAVEOLIN 1; ENDOCYTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RECEPTOR, IGF TYPE 1; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84876219516     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8848     Document Type: Review

References (68)

1. Bastiani M, Parton RG. Caveolae at a glance. J Cell Sci 2010, 123: 3831-6.
2. Razani B, Wang XB, Engelman JA, et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol 2002, 22: 2329-44.
3. Parolini I, Sargiacomo M, Galbiati F, et al. Expression of caveolin- 1 is required for the transport of caveolin-2 to the plasma membrane: retention of caveolin-2 at the level of the Golgi complex. J Biol Chem 1999, 274: 25718-25.
4. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 293: 2449-52.
5. Galbiati F, Engelman JA, Volonte D, et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem 2001, 276: 21425-33.
6. Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem 2002, 277: 41295-8.
7. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 1997, 272: 6525-33.
8. Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 2003, 3: 571-81.
9. Aboulaich N, Vainonen JP, Stralfors P, Vener AV. Vectorial proteomics reveal targeting, phosphorylation and specific fragmentation of polymerase I and transcript release factor (PTRF) at the surface of caveolae in human adipocytes. Biochem J 2004, 383: 237-48.
10. Briand N, Dugail I, Le Lay S. Cavin proteins: New players in the caveolae field. Biochimie 2011, 93: 71-7.
11. Jansa P, Mason SW, Hoffmann-Rohrer U, Grummt I. Cloning and functional characterization of PTRF, a novel protein which induces dissociation of paused ternary transcription complexes. Embo J 1998, 17: 2855-64.
12. Aboulaich N, Örtegren U, Vener AV, Strålfors P. Association and insulin regulated translocation of hormone-sensitive lipase with PTRF. Biochem Biophys Res Commun 2006, 350: 657-61.
13. Hill MM, Bastiani M, Luetterforst R, et al. PTRF-cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 2008, 132: 113-24.
14. Liu L, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem 2008, 283: 4314-22.
15. Bai L, Deng X, Li J, et al. Regulation of cellular senescence by the essential caveolar component PTRF/Cavin-1. Cell Res 2011, 21: 1088-101.
16. Hayer A, Stoeber M, Bissig C, Helenius A. Biogenesis of caveolae: stepwise assembly of large caveolin and cavin complexes. Traffic 2010, 11: 361-82.
17. Lee H, Volonte D, Galbiati F, et al. Constitutive and growth factorregulated phosphorylation of caveolin1 occurs at the same site (Tyr14) in vivo: identification of a cSrc/Cav1/Grb7 signaling cassette. Mol Endocrinol 2000, 14: 1750-75.
18. Panetta D, Biedi C, Repetto S, Cordera R, Maggi D. IGF-I regulates caveolin 1 and IRS1 interaction in caveolae. Biochem Biophys Res Commun 2004, 316: 240-3.
19. Biedi C, Panetta D, Segat D, Cordera R, Maggi D. Specificity of insulin- like growth factor I and insulin on Shc phosphorylation and Grb2 recruitment in caveolae. Endocrinology 2003, 144: 5497-503.
20. Schlegel A, Arvan P, Lisanti MP. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation: protein sorting at the level of the endoplasmic reticulum. J Biol Chem 2001, 276: 4398-408.
21. Aboulaich N, Chui PC, Asara JM, Flier JS, Maratos-Flier E. Polymerase I and transcript release factor regulates lipolysis via a phosphorylation- dependent mechanism. Diabetes 2011, 60: 757-65.
22. Jansa P, Burek C, Sander EE, Grummt I. The transcript release factor PTRF augments ribosomal gene transcription by facilitating reinitiation of RNA polymerase I. Nucleic Acids Res 2001, 29: 423-9.
23. Schmelzle K, Kane S, Gridley S, Lienhard GE, White FM. Temporal dynamics of tyrosine phosphorylation in insulin signaling. Diabetes 2006, 55: 2171-9.
24. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012, 12: 159-69.
25. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007, 28: 20-47.
26. Maggi D, Biedi C, Segat D, Barbero D, Panetta D, Cordera R. IGFI induces caveolin 1 tyrosine phosphorylation and translocation in the lipid rafts Biochem Biophys Res Commun 2002, 295: 1085-9.
27. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997, 387: 569-72.
28. Chen J, Capozza F, Wu A, et al. Regulation of insulin receptor substrate- 1 expression levels by caveolin-1. J Cell Physiol 2008, 217: 281-9.
29. Salani B, Passalacqua M, Maffioli S, et al. IGF-IR internalizes with caveolin-1 and PTRF/cavin in HaCat cells PLoS One 2010, 5: e14157.
30. Brodt P, Fallavollita L, Khatib AM, Samani AA, Zhang D. Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor β subunit. J Biol Chem 2001, 276: 33608-15.
31. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004, 29: 233-42.
32. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKTa major therapeutic target. Biochim Biophys Acta 2004, 1697: 3-16.
33. Navarro M, Baserga R. Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor Endocrinology 2001, 142: 1073-81.
34. Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin- 6- and insulin-like growth factor i-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 2003, 278: 5794-801.
35. Salani B, Briatore L, Garibaldi S, Cordera R, Maggi D. Caveolin-1 down-regulation inhibits insulin-like growth factor-i receptor signal transduction in H9C2 rat cardiomyoblasts. Endocrinology 2008, 149: 461-5.
36. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007, 120: 2479-87.
37. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96: 857-68.
38. Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 2009, 15: 752-7.
39. Di Fiore PP, De Camilli P. Endocytosis and signaling. An inseparable partnership. Cell 2001, 106: 1-4.
40. Zapf A, Hsu D, Olefsky JM. Comparison of the intracellular itineraries of insulin-like growth factor-I and insulin and their receptors in Rat-1 fibroblasts. Endocrinology 1994, 134: 2445-52.
41. Monami G, Emiliozzi V, Morrione A. Grb10/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization. J Cell Physiol 2008, 216: 426-37.
42. Sehat B, Andersson S, Girnita L, Larsson O. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 2008, 68: 5669-77.
43. Martins AS, Ordonez JL, Amaral AT, et al. IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis. PLoS One 2011, 6: e19846.
44. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of β1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res 2003, 63: 5850-8.
45. Salani B, Briatore L, Contini P, et al. IGF-I induced rapid recruitment of integrin β1 to lipid rafts is Caveolin-1 dependent. Biochem Biophys Res Commun 2009, 380: 489-92.
46. Echarri A, Del Pozo MA. Caveolae internalization regulates integrin- dependent signaling pathways. Cell Cycle 2006, 5: 2179-82.
47. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993, 90: 11217-21.
48. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, Sciacca L. Type I insulinlike growth factor receptor function in breast cancer. Breast Cancer Res Treat 1998, 47: 255-67.
49. Razani B, Schlegel A, Liu J, Lisanti MP. Caveolin-I, a putative tumour suppressor gene Biochem Soc Trans 2001, 29: 494-9.
50. Sagara Y, Mimori K, Yoshinaga K, et al. Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer 2004, 91: 959-65.
51. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 1999, 255: 580-6.
52. Wiechen K, Diatchenko L, Agoulnik A, et al. Caveolin-1 is downregulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001, 159: 1635-43.
53. Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007, 13: 90-101.
54. Li L, Yang G, Ebara S, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001, 61: 4386-92.
55. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. Upregulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002, 161: 1647-56.
56. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 2001, 46: 249-56.
57. Sunaga N, Miyajima K, Suzuki M, et al. Different roles for caveolin- 1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004, 64: 4277-85.
58. Li T, Sotgia F, Vuolo MA, et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor β-positive status. Am J Pathol 2006, 168: 1998-2013.
59. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003, 107: 873-7.
60. Glait C, Tencer L, Ravid D, Sarfstein R, Liscovitch M, Werner H. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways Exp Cell Res 2006, 312: 3899-908.
61. Matthews LC, Taggart MJ, Westwood M. Modulation of caveolin- 1 expression can affect signalling through the phosphatidylinositol 3-kinase/Akt pathway and cellular proliferation in response to insulin- like growth factor I. Endocrinology 2008, 149: 5199-208.
62. Salani B, Maffioli S, Hamoudane M, et al. Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. Faseb J 2011, 26: 788-98.
63. Aung CS, Hill MM, Bastiani M, Parton RG, Parat MO. PTRF-cavin- 1 expression decreases the migration of PC3 prostate cancer cells: role of matrix metalloprotease 9. Eur J Cell Biol 2011, 90: 136-42.
64. Gould ML, Williams G, Nicholson HD. Changes in caveolae, caveolin, and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression. Prostate 2010, 70: 1609-21.
65. Zou H, Stoppani E, Volonte D, Galbiati F. Caveolin-1, cellular senescence and age-related diseases. Mech Ageing Dev 2011, 132: 533-42.
66. Fontana L, Partridge L, Longo VD. Extending healthy life span- from yeast to humans. Science 2010, 328: 321-6.
67. Vitale G, Brugts MP, Ogliari G, et al. Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring. Aging (Albany NY) 2012, 4: 580-9.
68. Guha U, Chaerkady R, Marimuthu A, et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 2008, 105: 14112-7.